Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.
Latest From Market Access
The Boston Consulting Group convened a roundtable of market access executives from leading biopharma companies in the US, Europe and Japan to reach consensus on how to finance the cost of health care. The group's working paper considers various approaches to financing high-quality care, with an initial emphasis on advocating for change among payers in Europe.
Cell and gene therapies that have the potential to cure require new approaches to value assessment, payment and financing. In the second of a series, the Alliance for Regenerative Medicine identifies potential payment models, highlights key stakeholder concerns and identifies the barriers that must be addressed to enable their integration across the health care system.
The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting awhile, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.
Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.
The smart money had increasingly been on a hung parliament in the UK, with the ruling Conservative party being punished for several policy slip-ups, perceived dithering by Prime Minister Theresa May and her insistence on a clean and hard Brexit led by her alone. The June 8 election did not need to be called, and today, May is ruing the fact that she has lost both the party's absolute majority and her mandate to lead on a hard Brexit.
Health technology assessment for medtech products in Europe is a strictly national responsibility, but is there a case for an EU-wide HTA system that could improve medtech market access? MedTech Europe chief executive Serge Bernasconi shares his views with In Vivo.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.